The lack of meaningful P/E or EV/EBITDA multiples underscores the company's pre-revenue status and the speculative nature of its valuation. Investors should monitor whether this valuation floor holds as the company approaches critical data readouts, as any failure in the clinical pipeline could lead to a further collapse in the share price toward liquidation value.

The volatility in the current ratio, which dropped as low as 0.75 in 2025Q2, highlights the precarious nature of the company's working capital management. Given the absence of revenue, the current liquidity position appears highly sensitive to the timing of clinical trial expenditures, leaving little room for operational errors or unexpected regulatory delays.

The inability to generate positive returns on invested capital is a structural feature of the current development-stage model rather than a temporary operational failure. Analysts should interpret these negative returns as a reflection of the high-risk, high-reward nature of the Decoy platform, where capital is consumed entirely by the pursuit of proof-of-concept.